p, Virion [Release] |
Remdesivir alone [Beigle et al.,
2020] |
RCT of intravenous remdesivir in adults hospitalized with
evidence of lower respiratory tract involvement, showed improved median
recovery time of 11 vs 15 days. |
c Virion [Kill] |
Antibodies, convalescent plasma, vaccines |
Under
investigation |
δ, Productive Cell [Death]
p, Virion [Release]
|
Interferon-b-1b, ribavirin [Hung et al., 2020]
Protease inhibitors
|
Open label, prospective, randomized early treatment study (median 5
days, [IQR 3-7 days] since symptom onset) showed triple combination
reduced viral shedding by 5 days sooner versus Lop/r alone
|
β, Target Cell [Infection]
δ, Productive Cell [Death]
p, Virion [Release]
|
Hydroxychloroquine
Azithromycin
|
Small case series with multiple issues with trial design and no
comparator group limit inferences on virologic or clinical efficacy
(Guatret et al., 2020). Concerns on QT prolongation (Mercuro et al.,
2020)
|
|
Remdesivir + Hydroxycloroquine + lopinavir/ritonavir and/or interferon |
Potential RDV triple or quad combination antiviral regimen that covers
three parts of viral cell cycle |